Related Experiment Videos
Integrative Mendelian Randomization and Single-Cell Pseudotime Analysis Reveal DKK3 as a PI3K-AKT-Modulated Driver of
Zhanghao Huang1,2,3, Tiegang Cao1,2,3, You Lang Zhou4
1Medical School of Nantong University, Nantong University, Nantong, Jiangsu, China, ntu.edu.cn.
Background:
Esophageal squamous cell carcinoma (ESCC) remains a highly lethal malignancy, and the molecular drivers of its progression are not fully defined. Dickkopf-3 (DKK3), a context-dependent modulator of oncogenic signaling, has been implicated in several solid tumors, but its role in ESCC is unclear.
Methods:
We integrated Mendelian randomization based on cis-expression quantitative trait loci (cis-eQTLs) from 31,684 individuals with The Cancer Genome Atlas (TCGA) ESCC transcriptomic data (|log2FC| > 1 and p < 0.05) , single-cell RNA sequencing, and in vitro/in vivo functional assays to identify causal ESCC-associated genes. DKK3 expression was validated by Western blotting, its effects on ESCC cell proliferation, migration, and clonogenicity were tested experimentally, and DKK3-related pathways were explored by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses.
Results:
Integrative differential expression and MR analyses identified 22 ESCC-associated genes. Single-cell epithelial profiling further prioritized three candidates (DKK3, NINJ2, and SAPCD2), among which only DKK3 showed high and progressively increasing expression along the malignant epithelial trajectory and was therefore selected for mechanistic validation. DKK3 knockdown significantly inhibited ESCC cell proliferation, migration, and clonogenic capacity in vitro and suppressed tumor growth in nude mice. DKK3 silencing reduced p-PI3K and p-AKT levels, and enrichment analyses supported that DKK3 promotes ESCC progression at least partly through activation of the PI3K-AKT signaling pathway.
Conclusion:
By linking germline regulatory variation with single-cell tumor profiling and functional validation, this study identifies DKK3 as a causally relevant oncogenic regulator in ESCC that drives epithelial tumor growth and migration via PI3K-AKT pathway activation, supporting DKK3 as a potential biomarker and therapeutic targe.
Insights
Dickkopf-3 (DKK3) drives esophageal squamous cell carcinoma (ESCC) progression by activating the PI3K-AKT pathway. This study identifies DKK3 as a potential therapeutic target and biomarker for this lethal cancer.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Esophageal squamous cell carcinoma (ESCC) is a lethal cancer with undefined molecular drivers.
- The role of Dickkopf-3 (DKK3), a known modulator of oncogenic signaling, in ESCC is unclear.
Purpose of the Study:
- To identify causal genes driving ESCC progression.
- To investigate the specific role and mechanism of Dickkopf-3 (DKK3) in ESCC.
Main Methods:
- Integrated Mendelian randomization (MR) with cis-expression quantitative trait loci (cis-eQTL) data and The Cancer Genome Atlas (TCGA) ESCC transcriptomic data.
- Utilized single-cell RNA sequencing and in vitro/in vivo functional assays for gene prioritization and mechanistic validation.
- Analyzed DKK3 expression, its effects on ESCC cell behavior, and associated signaling pathways (Gene Ontology, KEGG).
Main Results:
- Identified 22 ESCC-associated genes, prioritizing DKK3, NINJ2, and SAPCD2.
- DKK3 expression increased along the malignant epithelial trajectory in ESCC.
- DKK3 knockdown inhibited ESCC cell proliferation, migration, and tumor growth, partly via PI3K-AKT pathway activation.
Conclusions:
- Dickkopf-3 (DKK3) is a causally relevant oncogenic regulator in ESCC.
- DKK3 promotes ESCC growth and migration through PI3K-AKT pathway activation.
- DKK3 represents a potential therapeutic target and biomarker for ESCC.
Related Concept Videos
Role Of Notch Signalling In Intestinal Stem Cell Renewal
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
PI3K/mTOR/AKT Signaling Pathway